Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
R131891-50mg | 50mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $112.90 | |
R131891-100mg | 100mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $179.90 | |
R131891-250mg | 250mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $326.90 | |
R131891-1g | 1g | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $919.90 | |
R131891-5g | 5g | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $3,219.90 |
Toll-like receptor 7 (TLR7) agonist
Synonyms | R848 | R 848 | S 28463 | R-848 | Resiquimod [INN] | 1-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol. | 1-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol | s28463 | R848;S28463 | Resiquimod (GMP |
---|---|
Specifications & Purity | Moligand™, ≥98%(HPLC) |
Biochemical and Physiological Mechanisms | Toll-like receptor 7 (TLR7) agonist. Induces upregulation of IL-6, IL-12, IFN-γand iNOS expression in mouse bone marrow-derived macrophages (BMMs). Inhibits RANKL-induced osteoclast differentiation in mouse BMMs and human peripheral blood monocytes. Also |
Storage Temp | Store at -20°C,Argon charged |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Agonist of TLR7;Agonist of TLR8 |
Note | 200mg 售完停产 |
ALogP | 1.3 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol |
---|---|
INCHI | InChI=1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19) |
InChi Key | BXNMTOQRYBFHNZ-UHFFFAOYSA-N |
Canonical SMILES | CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N |
Isomeric SMILES | CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N |
WGK Germany | 3 |
RTECS | NJ5911320 |
PubChem CID | 159603 |
Molecular Weight | 314.38 |
Wikipedia | Resiquimod |
---|---|
ChEBI | CHEBI:36706 |
CAS Registry No. | 144875-48-9 |
PubChem CID | 159603 |
ChEMBL Ligand | CHEMBL383322 |
RCSB PDB Ligand | RX8 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
G2401033 | Certificate of Analysis | Jul 10, 2024 | R131891 |
G2409127 | Certificate of Analysis | Jun 22, 2024 | R131891 |
G2409128 | Certificate of Analysis | Jun 22, 2024 | R131891 |
G2409129 | Certificate of Analysis | Jun 22, 2024 | R131891 |
G2409130 | Certificate of Analysis | Jun 22, 2024 | R131891 |
G2409131 | Certificate of Analysis | Jun 22, 2024 | R131891 |
F2414041 | Certificate of Analysis | Jun 20, 2024 | R131891 |
H2222101 | Certificate of Analysis | Jun 20, 2024 | R131891 |
H2222106 | Certificate of Analysis | Jun 20, 2024 | R131891 |
H2222107 | Certificate of Analysis | Jun 20, 2024 | R131891 |
D2416463 | Certificate of Analysis | Mar 11, 2024 | R131891 |
D2428397 | Certificate of Analysis | Mar 11, 2024 | R131891 |
H2222098 | Certificate of Analysis | Aug 02, 2022 | R131891 |
H2331037 | Certificate of Analysis | Aug 02, 2022 | R131891 |
I2305257 | Certificate of Analysis | Aug 02, 2022 | R131891 |
Solubility | Solvent:DMSO, Max Conc. mg/mL: 31.44, Max Conc. mM: 100; Solvent:ethanol, Max Conc. mg/mL: 15.72, Max Conc. mM: 50 |
---|---|
Sensitivity | Moisture sensitive;Heat sensitive |
Melt Point(°C) | 193℃ |
WGK Germany | 3 |
---|---|
RTECS | NJ5911320 |
Starting at $40.90
1. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.. Nat Immunol, 3 (2): (196-200). [PMID:11812998] [10.1021/op500134e] |
2. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G, Bauer S. (2002) Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848.. Nat Immunol, 3 (6): (499). [PMID:12032557] [10.1021/op500134e] |
3. Stockfleth E, Hofbauer GFL, Reinhold U, Popp G, Hengge UR, Szeimies RM, Brüning H, Anliker M, Hunger T, Dummer R et al.. (2019) Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial.. Br J Dermatol, 180 (2): (297-305). [PMID:30171698] [10.1021/op500134e] |